LITERATURA

1. Ahrendt HJ, Nisand I, Bastianelli C et al. Efficacy, acceptability and tolerability o the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 μg of ethinylestradiol and 3 mg of drospirenone. Contraception. 2006;74:451–7.
2. Albertazzi P, Bottazzi M, Steel SA. Bone mineral density and depot medroxyprogesteron acetate, Contraception. 2006;73(6):577–83.
3. Annus J, et al. Comparative multicentre trial of three IUDs inserted immediately following delivery of the placenta. Contraception. 1980;22:9–18.
4. Archer B, Irwin D, Jensen K, et al. Depot medroxyprogesterone. Management of side-effects commonly associated with its contraceptive use. J Nurse Midwifery. 1997;42(2):104–11.
5. Archer DF, Raine T, Darney PJ, et al. An open-labeled noncomparative study to evaluate the vagina and cervix of NuvaRing users. Fertil Steril. 2002;78 (Suppl 1):S25.
6. Aribarg S, Aribarg A. Emotional reaction to female sterilization: a prospective study. J Med Assoc Thai. 1982;65(4):167–71.
7. Bancroft J, Sherwin BB, Alexandr GM, et al. Oral contraceptives, androgens and the sexuality of young women II. Arch Sex Behav. 1991(2):121–35.
8. Beerthuizen R, van Beek A, Massai R et al. Bone mineral density during longterm use of the progestagen contraceptive implant Implanon compared to a nonhormonal method of contraception. Hum Reprod. 2000;15(1):118–22.
9. Berdah J. Pros and cons of triphasic oral contraception. Contracept Fertil Sex. 1985;13(12):1205–10.
10. Berenson AB, Rickert VI, Grady JJ. A prospective study of effects of oral and injectable contraception on bone mineral density. Obstet Gynecol. 2000;95 Suppl 4:6S.
11. Bigrigg A, Evans M, Gbolade B, et al. Depo Provera. Position paper on clinicial use, effectiveness and side effects. Br J Famm Plann. 2000;26(1):50.
12. Bjarnadóttir RI, Geirsson RT, Gottfreósdóttir H. An open non-randomised comparative study on the efrect of desogestrel 0,075 mg/day vs an IUD on lactation. Acta Obstet Gynecol Scand. 1997;76:53.
13. Bjarnadottir RI, Tuppurainen M, Killick SR. Comparison of cycle control with combined contraceptive vaginal ring and oral levonorgestrel/ethinylestradiol. AJOG. 2002;186:389–95.
14. Black C, Kaye JA, Jick H. Clinical risk factors for venous thromboembolus in users of the combined oral contraceptive pill. Br J Clin Pharmacol. 2002;53:637–40.
15. Brinton LA, Vessey MP, Flavel R, Yates D. Risk factor for benign breast disease. American J Epidemiol. 1981;113:203–14.

16. Calzolari E, Vittucci M, Colicchia A. Clinical evaluation of recent Cu-IUD. Patol Clin Obstet Ginecol. 1980;8(6):484–92.
17. Camp SL, Wilkerson DS, Raine TR. The benefits and risk sof ever--the-counter availability of emergency contraception. Contraception. 2003;68:309–17.
18. Canavan TP. Appropriate use of the IUD. American Fam Phys. 1998:1965–74.
19. Cibula D, et al. Základy gynekologické endokrinologie. Praha: Grada; 2002.
20. Coelingh Bennink HJT, Skouby S, Bouchard P, Holinka CF. Ovulation inhibition by estetrol in an in vivo model. Contraception. 2008;77:186–90.
21. Cohen J. Effects of oral contraceptives on sexual behavior. Contracept Fertil Sex. 1976;4(8):677–82.
22. Collaborative Group on Hormonal Factors in Breast Cancer: Breast Cancer and hormonal contraceptives. Lancet. 1996;347:1713–27.
23. Cooper C, et al. Oral contraceptive pill use and fractures in women: a prospective study. Bone. 1993;14:41–5.
24. Countinho EM, O´ Dwyer E, Barbosa IC, et al. Comparative study on intermittent versus continuous use of a contraceptive pill administered by vaginal route. Contraception. 1995;51:355–8.
25. Curtis KM, Martins SL. Progestogen-only contraception and bone mineral density: a systematic review. Contraception. 2006;73(5):470–87.
26. Čepický P, et al. Doporučení k předpisu COC. Čes Gynek. 2000;65/4:279–82.
27. Čepický P, Cibula D, Dvořák K, et al. Doporučení k předpisu kombinované hormonální kontracepce. Čes Gynek. 2005;70(4):320–4.
28. Čepický P, Dvořák K, Dvořák V, et al. Doporučení k předpisu gestagenní kontracepce. Čes Gynek. 2001;66(2):140–2.
29. D'Souza R, Guillebaud MA. Risks nad benefits or oral contraceptive pills. Best Pract Res Clin Obstet Gynecol. 2002;16(2):133–54.
30. DeCherney A. Bone-sparing properties of oral contraceptives. AJOG. 1996;174(1/1):15–20.
31. Delgado-Rodriguez M, Sillero-Arenas M, Moreno-Martin JM, et al. Oral contraceptives and cancer of the cervix. Acta Obstet Gynecol Scand. 1992;71:368–76.
32. Dinger JC, Heinemann LAJ, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive. Contraception. 2007;75:344–54.
33. Dulíček P. Riziko venózního tromboembolismu. Mod gyn por. 2010;19(1)Suppl B:86–92.
34. Endrikat J, Jaques MA, Mayerhofer M, et al. A twelve-month comparative clinical invetigation of two low-dose oral contraceptives. Contraception. 1995;52:229–35.
35. Enzelsberger H et al. Influence of oral contraceptive use on bone density in climacteric women. Maturitas. 1988;9:375–8.
36. Farley TM, et al. Intrauterine device and pelvic inflamatory disease. Lancet. 1992;339:785–8.
37. Fernandez E, la Vecchia C, Franceschi S, et al. Oral contraceptive use and risk of colorectal cancer. Epidemiology. 1998;9:295–300.
38. Frank P, Kay CR. Incidence of thyroid disease associated with oral contraceptives. BMJ. 1986;293:359–62.

39. Freeman E, Kroll R, Rapkin A, et al. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med. 2001;10(6):561–9.
40. Gallo MF, Grimes DA, Schulz KF, Helmerhorst FM. Combination estrogen-progestin contraceptives and body weight: systematic review of randomized controlled trials. Obstet. Gynecol. 2004;103:359–73.
41. Gallo MF, Lopez LM, Grimes DA, et al. Combination contraceptives: effects on weight. Cochrane Database Syst. Rev. 2008;4:CD003987.
42. Gambrell RD, Bernard DM, Sanders BI, et al. Changes in sexual drives on oral contraceptives. J Reprod Med. 1976;3:165–71.
43. Garnero P, Sornay-Rendu E, Delmas PD. Decreased bone turnover in oral contraceptive users. Bone. 1995;16(5):499–503.
44. Glasier AF, Cameron ST, Fine PM, et al. Ulipristalacetate versus levonorgestrel for emergency contraception. Lancet. 2010;375:555–62.
45. Godet PG, May GR, Sutherland LR. Meta-analysis of the role of oral contraceptive agents in inflammatory bowel disease. Gut. 1995; 37:668–73.
46. Graham CA, Sherwin BB. The relationship between mood and sexuality in women using oral contraceptive as a treatment for premenstrual symptoms. Psychoendocrinol. 1993;18(4):273–81.
47. Grimes DA, Schulz KF. Antibiotic prophylaxis for intrauterine device insertion. Cochrane Library. Is. 1. Oxford; 2003.
48. Gross TP, Schlesselman, JJ. The estimated effect of oral contraceptive use on the cumulative risk of epitelial ovarian cancer. Obstet Gynecol. 1994;83:419–24.
49. Gwin ML. Oral contraceptives and breast, endometrial, and ovarian cancers. J Obstet Gynaecol. 1985;Suppl 2:S 83–7.
50. Heikkila M, Haukkamaa M, Luukkainen T. Levonorgestrel in milk and plasma of breast-feeding women with LNG-releasing IUD. Contraception. 1982;1:41–9.
51. Chasan-Taber L, Willet WC, Manson JE et al. Prospective study of oral contraceptives and hypertension among women in the United States. Circulation. 1996;94:483–9.
52. Christin-Maitre S, Serfaty D, Chabbert-Buffet N, et al. Comaprison of a 24-day and 21-day pll regimen for the novel combined oral contaceptive NOMAC/E2. Human Reprod. 2011;26(6):1338–47.
53. Jick H, Jick SS, Gurewid V, et al. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptive with different progestagen components. Lancet. 1995;346:1589–93.
54. Karlsson R, Linden A, von Schoultz B. Suppression of 24-hour cholecystokinin secretion by oral contraceptives. AJOG. 1992;167(1):58–9.
55. Kleerekoper M, Brienza RS, Schulz LR. Oral contraceptive use may protect against low bone mass. Arch Intern Med. 1991;151:1971–6.
56. Klipping C, Duijkers I, Trummer D, Marr J. Supression of ovarian activity with drospirenone-containing oral contraceptive in 24/4 regimen. Contraception. 2008;78:16–25.
57. Koetsawang S, Chiemprasert T, Premyodhin M. Long term effects of oral contraception. Asian Med J. 1972;8:10–6.
58. Koltun W, Lucky AW, Thiboutot D, et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administe-

red in 24/4 regimen in the treatment of acne vulgaris. Contraception. 2008;77:249–56.
59. Kritz-Silverstein D, Barret-Connor E. Bone mineral density in postmenopausal women as determined by prior oral contraceptive use. Am J Public Health. 1993;83:100–2.
60. Kunitz AM. Depot medroxyprogesterone acetate contraception and the risk of breast and gynecologic cancer. J Reprod Med. 1996;41 Suppl 5:419–27.
61. Kuohung W, Borgatta L, Stubblefield P. Low-dose oral contraceptives and bone mineral density: an evidence based analysis. Contraception. 2000;61:77–82.
62. Lewis MA, Heinemann LAJ, Spitzer WO, et al. The use of oral contraceptives and the occurence of acute myocardial infarction in young women. Contraception. 1997;56:129–40.
63. Lidegaard O, Edström B, Kreiner S. Oral contraceptives and venous tromboembolism: five-year national case-control study. Contraception. 2002;65(3):183–96.
64. Mais V, et al. Bone metabolism in young women taking a monophasic pil containing 20 mcg ethinylestradiol: prospective study. Contraception. 1993;48:445–52.
65. Marshall LM, Spiegelman D, Goldman NB, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril. 1998;70(3):432–9.
66. Marston C, Meltzer H, Majeed A. Impact of contraceptive praktice of making emergency contraception available over the counter in Great Britain. BMJ. 2005;331:271–3.
67. Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a radomized trial. Obstet Gynecol. 2003;101:653–61.
68. Milson I, Lete I, Bjertnaes A, et al. Effects on cycle control and bodyweight of the contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 µg ethinylestradiol and 3 mg drospirenon. Hum Reprod. 2006;21(9):2304–11.
69. Moore C, Luderschmidt C, Moltz L, et al. Antiandrogenic properties of the dienogest-containing oral contraceptive Valette. Drugs Today. 1999;35(Suppl C):69–78.
70. Murphy S, Khaw KT, Compston JE. Lack of relationship between hip and spine bone mineral density and oral contraceptive use. Eur J Clin Invest. 1993;23:108–11.
71. Neuberger J, Forman D, Doll R, Williams R. Oral contraceptives and hepatocellular carcinoma. BMJ. 1986;292:1355–7.
72. Oddens BJ. Women's satisfaction with birth control: a population survey of physical and psychological effects of oral contraceptives, intrauterine devices, condoms, natural femily planning and sterilization among 1446 women. Contraception. 1999;59(5):277–86.
73. Oddson K, Leifels-Fischer B, Wiel-Masson D, et al. Superior cycle kontrol with a contraceptive vaginal ring compared with an oral contraceptive containing 30µg ethinylestradiol and 150µg levonorgestrel:a randomized trial. Hum Reprod. 2005;20(2):557–62.
74. Odlind V, Misom I, Persson I, et al. Can changes in sex hormone binding globuline predict the risk of venous trombembolism with

combined oral contraceptive pills? Acta Obstet Gynecol Scand. 2002;81:482–90.
75. Oelkers W. Antimineralocorticoid activity of a novel oral contraceptive containing drospirenone, a unique progestogen resembling natural progesterone. Eur J Contracept Reprod Health Care. 2002;7 Suppl 3:19–26.
76. Olsson J, Jernstrom H, Alm P, et al. Proliferation of the breast epitelium in relation to menstrual cycle phase, hormonal use, and reproducitve factors. Breast Cancer Res Treat. 1996;40:187–96.
77. Parke S, Nahum GG, Mellinger U, Junge W. Metabolic effects of a new four-phasic oral contraceptive containing estradiol valerate and dienogest. Obstet Gynecol. 2008;111(4) Suppl:12S–3S.
78. Paoletti AM, et al. Evidence that treatment with monophasic oral contraceptive formulations containing ethinylestradiol plus gestodene reduces bone resorption in young women. Contraception. 2000;61:259–63.
79. Pearlstein TB, Bachmann GA, Zacur HA, et al. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005;72:414–21.
80. Peterson HB et al. The risk of pregnancy after tubal sterilisation: findings from the US collaborative review of sterilization. AJOG. 1996;174:1161–70.
81. Polatti F, et al. Bone mass and long-term monophasic oral contraceptive treatment in young women. Contraception. 1995;51:221–4.
82. Rabe T, Kowald A, Ortmann J et al. Inhibition of skin 5alfa-reductase by oral contraceptive progestin in vitro. Gynecol Endocrinol. 2000;14:223–30.
83. Raudrant D, Rabe T. Progestogens with antiaandrogenic properties. Drugs. 2003;63 (5):463–92.
84. RCGP Oral Contraception Study: Reduction in the incidence of rheumatoid arthritis associated with oral contraceptives. Lancet. 1978;1:569–70.
85. Rohr UD. The impact of testosterone imbalance on depression and women's health. Maturitas. 2002;41 Suppl 1:S25–46.
86. Rosenfield AG, Castadot RG. Early postpartum and immediate postpartum intrauterine contraceptive device insertions. AJOG. 1974;118:1104–14.
87. Ross RK, Pike MC, Vessey MP et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. BMJ. 1986;293:359–62.
88. Roumen FJ, Apter D, Mulders TM, et al. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinylestradiol. Hum Reprod. 2001;16:469–75.
89. Schlesselman JJ. Oral contraceptives and neoplasia of the uterine corpus. Contraception. 1991;43:557–79.
90. Spinillo A, Gorini G, Piazzi G, et al. The impact of oral contraception on chlamydial infection among patients with pelvic inflamatory disease. Contraception. 1996;54:163–8.
91. Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception. 1996;54:71–7.

92. Stachenfeld NS. Sex hormone effects on body fluid regulation. Exerc Sport Sci Rev. 2008;36:152–9.
93. Suchopár J et al. Kompendium lékových interakcí Infopharm®. 2005.
94. Sulak PJ. et al. Hormone withdrawal symptoms in OC users. Optet Gynecol. 2000;95(2):261–6.
95. Thorogood M. Stroke and steroid hormonal contraception. Contraception. 1998;53 Suppl I:S19–25.
96. Timmer CJ, Mulders TM. Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ring. Clin Pharmacokinet. 2000;39:233–42.
97. Tonkelaar I, Oddens BJ. Prefered frequency and characteristics of menstrual bleeding in relation to reproductive status, OCuse and HRT use. Contraception. 1999;59:357–62.
98. Trussell J. Contraceptive effi cacy. In: Hatcher RA, Trussell J, Stewart R. Contraceptive Technology. 17th ed. New York NY: Ardent Media; 1998. p. 800–1.
99. Tuckey J. Combined oral contraception and cancer. Brit J Fam Plan. 2000;26:237–40.
100. van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005;72(3):168–74.
101. Vasilakis-Scarmozza C, Jick H. Risk of venous tromboembolism with cyproterone or levonorgestrel contraceptives. Lancet. 2001; 358(9291):1427–9.
102. Veres S, Miller L, Burington B. A comparison between the vaginal ring and oral contraceptive. Obstet Gynecol. 2004;104(3):553–63.
103. Visser M, Coellingh Bennink HJT. Clinical application for estetrol. J Steroid Biochem Mol Biol. 2009;114:85–9.
104. Wallach EE, Gyrcia C. Psychodynamic aspects of oral contraception. JAMA. 1968;203(11):927–31.
105. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet. 1997;349:102–9.